Pahr Therapeutics

Pahr Therapeutics is a clinical-stage biotechnology company dedicated to developing new therapies for pulmonary arterial hypertension through innovative molecular mechanisms. The company provides cutting-edge treatments targeting the molecular pathophysiology of polycyclic aromatic hydrocarbons (PAH), enabling patients to access potentially life-saving therapies. It addresses unmet needs in PAH treatment, bringing new hope to areas where traditional options fall short.